BSE Live
Apr 10, 16:01Prev. Close
730.05
Open Price
738.65
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 10, 15:50Prev. Close
725.80
Open Price
736.70
Bid Price (Qty.)
732.00 (97)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Albert David (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 511.42 | 97.29 | 50.74 | 47.30 | 27.44 | |
| Net CashFlow From Operating Activities | -28.44 | 45.50 | 10.52 | 40.36 | 36.61 | |
| Net Cash Used In Investing Activities | 23.30 | -33.25 | -5.00 | -39.70 | -36.68 | |
| Net Cash Used From Financing Activities | 0.11 | -8.27 | -6.36 | -4.88 | -1.71 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.01 | 0.01 | 0.08 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -5.02 | 3.99 | -0.83 | -4.13 | -1.77 | |
| Cash And Cash Equivalents Begin of Year | 5.44 | 1.45 | 2.28 | 2.64 | 6.42 | |
| Cash And Cash Equivalents End Of Year | 0.42 | 5.44 | 1.45 | -1.49 | 4.64 |
25.02.2026
Albert David Standalone December 2025 Net Sales at Rs 89.93 crore, up 8.24% Y-o-Y
13.11.2025
Albert David Standalone September 2025 Net Sales at Rs 87.24 crore, down 11.37% Y-o-Y
05.08.2025
Albert David Standalone June 2025 Net Sales at Rs 70.57 crore, down 21.03% Y-o-Y
13.05.2025
Albert David Standalone March 2025 Net Sales at Rs 74.89 crore, down 15.9% Y-o-Y
25.02.2026
Albert David Standalone December 2025 Net Sales at Rs 89.93 crore, up 8.24% Y-o-Y
13.11.2025
Albert David Standalone September 2025 Net Sales at Rs 87.24 crore, down 11.37% Y-o-Y
05.08.2025
Albert David Standalone June 2025 Net Sales at Rs 70.57 crore, down 21.03% Y-o-Y
13.05.2025
Albert David Standalone March 2025 Net Sales at Rs 74.89 crore, down 15.9% Y-o-Y
10.04.2026
09.04.2026
08.04.2026
Indian CDMOs face tariff exposure via patented drug supply chains
08.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth